Request Demo

Last update 08 May 2025

Dihydroergocryptine/Caffeine

Last update 08 May 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Vasobral, 洛斯宝

Target

A1R x A2aR x DRDs

Action

antagonists, agonists

Mechanism

A1R antagonists(Adenosine A1 receptor antagonists), A2aR antagonists(Adenosine A2a receptor antagonists), DRDs agonists(Dopamine receptors agonists)

Therapeutic Areas

Cardiovascular DiseasesEndocrinology and Metabolic DiseaseEye Diseases

Active Indication

Diabetes MellitusDiabetic Retinopathy

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC8H10N4O2

InChIKeyRYYVLZVUVIJVGH-UHFFFAOYSA-N

CAS Registry58-08-2

View All Structures (2)

100 Clinical Results associated with Dihydroergocryptine/Caffeine

100 Translational Medicine associated with Dihydroergocryptine/Caffeine

100 Patents (Medical) associated with Dihydroergocryptine/Caffeine

Literatures (Medical) associated with Dihydroergocryptine/Caffeine

01 Jan 2014·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

[Efficacy of the combination drug vasobral in chronic vascular encephalopathy].

Article

Author: Psokhina, O V ; Kopishinskaya, S V ; Radiuk, M A ; Lukashevich, I G ; Levin, O S ; Belskaya, G N ; Barantsevich, E R ; Ostroumova, O D ; Vasenina, E E

OBJECTIVEDespite the high prevalence of chronic vascular encephalopathy, its diagnosis and treatment remain understudied. This observational multicenter trial assessed the efficacy and safety of vasobral in patients with cerebral ischemia.MATERIAL AND METHODSThe open observational study was carried out in 37 centers in 11 Russian cities and included 300 patients with confirmed diagnosis of chronic vascular encephalopathy, stages 1 and 2, without dementia. The patients received 1 tablet (4 mg α-dihydroergocryptine and 40 mg caffeine) 2 times a day during 3 months.RESULTS AND CONCLUSIONThere was an improvement of cognitive and affective status as well as quality of life and a decrease of subjective signs of chronic vascular encephalopathy. Vasobral did not cause significant fluctuations of arterial pressure and was safe for patients with chronic vascular encephalopathy and arterial hypertension.

01 Jan 2013·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

[Vasobral in the treatment of brain lesions: views of physicians and patients].

Article

Author: Kamchatnov, P R

A study was based on the survey of 419 neurologists and 1189 their patients with different forms of cerebrovascular diseases using a specially developed questionnaire. In most cases, vasobral was used as a monotherapy or in a complex treatment. Twenty-two percent of physicians reported that vasobral was the most effective compared to other drugs. The good tolerability of treatment (18%) and the broad spectrum of indications and clinical effects (17%) were reported as well. The large percentage (75%) of patients indicated the positive effect of vasobral on memory, reasoning, vertigo etc The maximal effect was identified in the treatment of mild cognitive impairment caused by chronic brain ischemia and vertebrobasilar insufficiency. Vasobral is recommended for a use in a complex therapy in patients with more severe brain lesions and cognitive deficit.

01 Jan 2011·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

[The use of vasobral in patients with chronic cerebrovascular disorders].

Article

Author: Kamchatnov, P R

100 Deals associated with Dihydroergocryptine/Caffeine

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus	China	-	-
Diabetic Retinopathy	China	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Dihydroergocryptine/Caffeine

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation